Spero Therapeutics Inc (NASDAQ:SPRO) CEO Ankit Mahadevia sold 754 shares of the business’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $14.25, for a total value of $10,744.50. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Ankit Mahadevia also recently made the following trade(s):
- On Thursday, July 9th, Ankit Mahadevia sold 2,293 shares of Spero Therapeutics stock. The shares were sold at an average price of $14.31, for a total value of $32,812.83.
Shares of NASDAQ:SPRO opened at $13.61 on Friday. Spero Therapeutics Inc has a twelve month low of $5.25 and a twelve month high of $14.48. The company has a current ratio of 4.31, a quick ratio of 4.31 and a debt-to-equity ratio of 0.05. The company has a market cap of $290.80 million, a PE ratio of -3.22 and a beta of 1.97. The company’s 50 day moving average is $12.90 and its 200 day moving average is $10.15.
Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings data on Friday, May 8th. The company reported ($1.22) EPS for the quarter, beating the consensus estimate of ($1.35) by $0.13. Spero Therapeutics had a negative net margin of 654.03% and a negative return on equity of 88.22%. The business had revenue of $1.70 million for the quarter, compared to the consensus estimate of $3.36 million. Equities research analysts predict that Spero Therapeutics Inc will post -4.15 earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of the business. State Street Corp grew its position in Spero Therapeutics by 33.5% during the 1st quarter. State Street Corp now owns 278,443 shares of the company’s stock worth $2,250,000 after purchasing an additional 69,852 shares during the period. VR Adviser LLC acquired a new position in shares of Spero Therapeutics in the 1st quarter valued at about $3,830,000. Squarepoint Ops LLC boosted its stake in shares of Spero Therapeutics by 13.3% in the first quarter. Squarepoint Ops LLC now owns 20,389 shares of the company’s stock worth $165,000 after buying an additional 2,386 shares during the last quarter. DAFNA Capital Management LLC acquired a new stake in Spero Therapeutics during the first quarter worth about $389,000. Finally, Rock Springs Capital Management LP raised its position in Spero Therapeutics by 15.2% during the first quarter. Rock Springs Capital Management LP now owns 605,000 shares of the company’s stock valued at $4,888,000 after acquiring an additional 80,000 shares in the last quarter. 52.88% of the stock is currently owned by institutional investors.
SPRO has been the topic of a number of research analyst reports. Zacks Investment Research lowered Spero Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, June 5th. Stifel Nicolaus dropped their target price on shares of Spero Therapeutics from $22.00 to $21.00 and set a “buy” rating on the stock in a research report on Tuesday, March 17th. Cantor Fitzgerald restated an “overweight” rating on shares of Spero Therapeutics in a research note on Tuesday, March 17th. HC Wainwright reiterated a “buy” rating and set a $28.00 price objective on shares of Spero Therapeutics in a research note on Tuesday, June 2nd. Finally, Oppenheimer assumed coverage on shares of Spero Therapeutics in a report on Friday, May 8th. They set a “buy” rating and a $20.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $21.00.
About Spero Therapeutics
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative infections in the hospital; and SPR720, an oral antibiotic for the treatment of pulmonary non-tuberculous mycobacterial disease.
See Also: How to invest in a bear market
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.